October 2026 - Corcept Therapeutics

2-Year Overall Survival Results From DAZALS: A Phase 2, Randomized Controlled Trial of Dazucorilant, a Selective Glucocorticoid Receptor Modulator, in Amyotrophic Lateral Sclerosis

October 29, 2026

Ladha et al. • 2026 • NEALS

Budget Impact of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer: A US Payer Perspective

October 27, 2026

Bjerke et al. • 2026 • AMCP Nexus

Infusion Chair Time and Clinic Visits as Drivers of Healthcare Resource Utilization in Platinum-Resistant Ovarian Cancer

October 27, 2026

Arn et al. • 2026 • AMCP Nexus

Pooled Safety Analysis of Relacorilant Plus Nab-paclitaxel in Patients With Platinum-resistant Ovarian Cancer Enrolled to ROSELLA and Study 552

October 26, 2026

Olawaiye et al. • 2026 • ESMO

Meta-analysis of Relacorilant Plus Nab-paclitaxel Efficacy in Patients With Platinum-resistant Ovarian Cancer (PROC) Enrolled to ROSELLA and Study 552

October 26, 2026

Olawaiye et al. • 2026 • ESMO

Relacorilant Provides Significant Benefit Across Cardiometabolic Outcomes in Global Statistical Tests of the Placebo-controlled, Randomized-withdrawal GRACE Trial in Cushing Syndrome

October 16, 2026

Hand et al. • 2026 • CMHC

Characteristics Associated With Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disorders: Analyses From the MOMENTUM Study

October 8, 2026

Al Dhaybi et al. • 2026 • AHA HTN